The day in pharma, read in minutes.
NewsTonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting
Tonix advances TNX-4800 following FDA feedback, supporting a Phase 2 study of its monoclonal antibody to prevent seasonal Lyme disease.
Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®
Acurx Receives Positive FDA Feedback on Ibezapolstat Phase 3 Development Program, FDA Signals Potential Single-Trial NDA Pathway
Decoy Therapeutics Expands Global Patent Portfolio for Antiviral Technology, Strengthens Intellectual Property Around D-MAV and IMP³ACT Platform
Chugai Pharmaceutical Becomes Healthcare Innovation Partner of Japan Basketball Association, Advance Sports and Health
Latest news
11 storiesNurix Therapeutics Enrolls First Patient In Phase 3 Trial Of Bexobrutideg For Relapsed Or Refractory CLL/SLL
Nurix Therapeutics enrolls the first patient in its Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg for relapsed or refractory CLL/SLL.
Sanofi Wins EU Approval To Expand MenQuadfi Vaccine Use To Infants From Six Weeks Of Age
Sanofi wins EU approval to expand MenQuadfi vaccine use to infants from six weeks of age, broadening protection against meningococcal disease.
Teladoc Health Appoints Former Verisk Executive Mark Anquillare to Board To Support Growth, Technology And AI Strategy
Teladoc Health appoints former Verisk executive Mark Anquillare to its Board to support growth, technology, and AI strategy initiatives.
AEON Biopharma Regains NYSE American Listing Compliance After $13.6 Million Public Offering Strengthens Shareholders' Equity
AEON Biopharma regains NYSE American listing compliance after a $13.6 million public offering strengthens its shareholders' equity position.
Mobia Medical Appoints Surgeon and Healthcare Executive Dr. Myriam Curet To Board To Support Growth Of Stroke Recovery Business
Mobia Medical appoints surgeon and healthcare executive Dr. Myriam Curet to its Board to support growth of its Vivistim stroke recovery therapy.
Codexis Appoints David Butler To Strategic Advisory Board To Support Growth In siRNA Manufacturing And Enzymatic Technologies
Codexis appoints David Butler to its Strategic Advisory Board to support growth in siRNA manufacturing and its enzymatic technology platform.
AIM ImmunoTech Completes Final Patient Dosing In Phase 2 DURIPANC Trial Of Ampligen For Metastatic Pancreatic Cancer Ahead Of Schedule
AIM ImmunoTech completes final patient dosing in its Phase 2 DURIPANC trial evaluating Ampligen for metastatic pancreatic cancer, ahead of schedule.
20260805131500.webp&w=1920&q=75&dpl=dpl_GGkXARwZ1w2xRMDJpZjTP7g1TvsA)
Cue Biopharma Appoints James Ahlers As Chief Financial Officer To Support Clinical Growth And Upcoming Development Milestones
Cue Biopharma appoints James Ahlers as Chief Financial Officer to support clinical growth and upcoming CUE-221 and CSU development milestones.
Achieve Life Sciences Strengthens Leadership Team With Two Senior Appointments As Cytisinicline Moves Closer To U.S. Commercial Launch
Achieve Life Sciences appoints Ronald Dadino as SVP of CMC/Supply Chain and Gloria Cosgrove as SVP of Quality as cytisinicline nears U.S. launch.
Altimmune Starts Global Phase 3 PERFORMA Trial To Evaluate Pemvidutide For MASH After Promising Mid-Stage Results
Altimmune starts its global Phase 3 PERFORMA trial evaluating pemvidutide for MASH liver disease, following promising Phase 2b clinical results.
Novo Nordisk's Experimental Heart Drug Misses Late-Stage Trial Goal, Raising Pressure To Diversify Beyond Obesity
Novo Nordisk's ziltivekimab misses its Phase III cardiovascular endpoint, intensifying pressure to diversify beyond obesity.
Worth your time this week
AstraZeneca And Bristol Myers Squibb Reportedly Held Early Merger Talks For Potential $400 Billion Pharma Giant
Novo Nordisk's Late-Stage Cardiovascular Drug Fails Key Trial, Shares Drop
Ascentage Pharma Appoints Faiçal Miyara As Chief Business Officer And Jim Ziegler As Chief Commercial Officer
